Norge - norsk - Statens legemiddelverk

teva b.v. - tolvaptan - tablett - 30 mg / 90 mg

Norge - norsk - Statens legemiddelverk

teva b.v. - tolvaptan - tablett - 30 mg / 60 mg

Norge - norsk - Statens legemiddelverk

teva b.v. - tolvaptan - tablett - 45 mg / 15 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - bryst neoplasms - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Norge - norsk - Statens legemiddelverk

orifarm as - metylprednisolon - tablett - 16 mg

Norge - norsk - Statens legemiddelverk

orion corporation - espoo - warfarinnatrium - tablett - 2.5 mg

Norge - norsk - Statens legemiddelverk

orifarm as - metylprednisolonnatriumsuksinat - pulver og væske til injeksjonsvæske, oppløsning - 1 g

Norge - norsk - Statens legemiddelverk

orifarm as - metylprednisolonnatriumsuksinat - pulver og væske til injeksjonsvæske, oppløsning - 1 g

Norge - norsk - Statens legemiddelverk

orifarm as - metylprednisolonnatriumsuksinat - pulver og væske til injeksjonsvæske, oppløsning - 1 g